News Releases

 
News Releases
  Date Title and Summary View
Dec 1, 2006
Miami, FL - December 1, 2006 — ChemoCentryx, Inc. is presenting clinical and preclinical data from studies of the company's drug candidate Traficet-EN® (CCX282-B) a first-in-class, orally active, anti-inflammatory agent that targets the chemokine receptor known as CCR9, at the 2006 Crohn's and Colitis Foundation of America's (CCFA...
Oct 24, 2006
Berlin, Germany — October 24, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company developing orally-administered therapeutics that target the chemokine and chemoattractant systems, today announced positive data from the company's Phase 2 clinical trial of Traficet-EN™ (CCX282-B) for the treatment of Crohn...
Aug 24, 2006
Mountain View, CA, USA; August 24, 2006 — ChemoCentryx, Inc. today announced that it has recently completed a Series C financing in June 2006 with participating investors including Jennison Associates, HBM BioVentures, Orbimed Advisors, Techne Corporation, Alta Partners, and GIMV. Gross proceeds from this round of financing totaled $1...
Aug 24, 2006
London, UK, Philadelphia, PA and Mountain View, CA, USA; August 24, 2006 — GlaxoSmithKline (NYSE: GSK) and ChemoCentryx, Inc. today announced a worldwide multi-target strategic alliance to discover, develop and market novel medicines targeting four chemokine and chemoattractant receptors for the treatment of a variety of inflammatory d...
Feb 7, 2006
Mountain View, CA; February 7, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced that the company has appointed Regina E. Herzlinger to the company's Board of Directors, effectiv...
Jan 5, 2006
Mountain View, CA; January 5, 2006 — ChemoCentryx, Inc., a clinical-stage, biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, today announced the appointment of Susan M. Kanaya to the post of Senior Vice President, Finance and Chief Financi...
Nov 22, 2005
Mountain View, CA; November 22, 2005 — ChemoCentryx, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine system, announced that the company has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Ad...
May 16, 2005
Chicago, IL; May 16, 2005 — ChemoCentryx, Inc. presented positive Phase 1 clinical and preclinical data from studies of the company's lead product for inflammatory bowel disease (IBD), Traficet-EN™ (CCX282) at the Digestive Disease Week 2005 conference being held in Chicago, Illinois May 14-19, 2005. These data indica...
Jan 6, 2005
January 6, 2005; Mountain View, Calif. — ChemoCentryx, Inc. today announced that the company is currently conducting a Phase II clinical trial to evaluate the safety and pharmacokinetics of one of the company's lead products, Traficet-EN™ (CCX282), among patients with inflammatory bowel disease (IBD). ...
Jun 17, 2004
June 17, 2004; San Carlos, Calif. — ChemoCentryx, Inc. today announced that it has closed a private financing round raising gross proceeds of $33 million. HBM BioVentures and Alta Partners acted as significant new investors in the round. Additional participants included new investors GIMV and Hanseatic, as well as returning investors...
Page: FirstPrevious ...
18
NextLast
= add release to Briefcase